ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Pumpkin Pie Turmeric Breakfast Smoothie - Vegan + Gluten-Free

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Vitamin D supplementation extends life in mouse model of Huntington's disease

Omega-3 fatty acid stops known trigger of lupus

Conquer Your Email Inbox, Increase Productivity and Reduce Stress

The Significance of Selenium

Print Page
Email Article

Trials of Omega-3 Supplementation for Depression Continue at Mass General

  [ 280 votes ]   [ Discuss This Article ]
By Editor • • January 17, 2007

Massachusetts General Hospital in Boston is recruiting subjects for a Phase III trial comparing the effectiveness of supplementation with two natural compounds commonly found in fish oils for treatment of major depression. Results will be measured in terms of subjects' scores on a depression rating scale over the course of the study.

The large trial, which will enroll 300 patients overall, is titled “Safety and effectiveness of Omega-3 Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression” ( Indentifier NCT00361374). This trial is sponsored by Mass General's Depression Clinical Research Program – an international leader in cutting edge depression research and treatment "with a focus on testing novel antidepressant treatments" – under principal investigator David Mischoulon, MD, PhD.

The present trial follows on the heels of a smaller Phase III trial of the Omega-3 fatty acid Ethyl-EPA for treating depression – results of which have yet to be published. That study was also conducted at Mass General under Dr. Mischoulon, and was sponsored by the National Center for Complementary and Alternative Medicine (NCCAM).

Study Rationale
It is believed that a deficiency in the two natural Omega-3 compounds involved – eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) – “may lead to the development of major depression,” the researchers note. The purpose of the trial: to determine whether and how Omega-3 supplementation "can be used safely and effectively to treat major depression."

Study Length and Design
The present interventional treatment trial will involve patient visits for screening and baseline measurements, plus four more visits (every two weeks for a period of eight weeks) for testing and scoring on a depression rating scale.

The trial is a “randomized, double-blind, placebo controlled, parallel assignment, safety/efficacy study.” Specifically:
n Qualifying participants will be randomized, or chosen by chance, to enter into one of three groups.
n People in the first group will take 1 gram per day of EPA omega-3 fatty acid.
n Those in the second group will take 1 gram per day of DHA omega-3 fatty acid.
n Those in the third group will take a placebo, or fake dose.
n Because the study is “double-blind,” neither the participant, nor the doctor, nor the research staff will know which group each person is in.
n But at the end of the study all participants will be offered three months of follow-up care in the Depression Clinical Research Program.

Applicants may be male or female, and any age between 18 and 80. They must meet the study criteria for current “Major Depressive Disorder.”

Exclusion Factors Include
n Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease.
n History of seizure disorder.
n Substance use disorders, including alcohol, active within the last six months (past history is OK).
n History of multiple adverse drug reactions or allergy to the study compounds.

For More Information and to Apply, Contact
Juliana A Smith, BA
Depression Clinical Research Program
Massachusetts General Hospital, Boston
Phone: (617) 724-2936 E-mail:
Refer to the study by identifier NCT00361374

Official Title: Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters.
Study ID Numbers: 2005P002337; 1 RO1 MH74085-01A1
Health Authority: US Institutional Review Board; US Food and Drug Administration

About the Mass General Depression Clinical Research Program
For more information on the DCRP, go to

To quote this site: "The DCRP is currently conducting cutting edge research in the area of depression, with a focus on testing novel antidepressant treatments and on developing new tools to understand the biological changes that occur in this condition. The successes of the Program in the area of depression have not only informed clinical practice, but in many cases have defined it for the field. The Program has gathered together over the years a large group of experienced researchers as well as promising young trainees and junior faculty, generating countless clinical reports, pilot studies, and large controlled trials. The staff at the DCRP have successfully obtained significant funding from both the National Institute of Mental Health and industry sources. Currently, there are more than 30 ongoing studies at the DCRP.

"In addition to carrying out significant research activities, the DCRP is involved in delivering excellent clinical care through the Outpatient Psychiatry Division at MG."

Note: The information provided here has not been evaluated by the FDA and is not meant to prevent, diagnose, treat, or cure and illness, condition, or disease. It is essential that you never make a change in your personal health support plan or regime without first researching and reviewing it in collaboration with your professional healthcare team.

Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Ultra ATP+, Double Strength Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Curcumin - a Golden Gift of Nature with Benefits Still Untold Curcumin - a Golden Gift of Nature with Benefits Still Untold
Could a B-12 Deficiency Be Causing Your Symptoms? Could a B-12 Deficiency Be Causing Your Symptoms?
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?
Thyroid Health and Fibromyalgia Thyroid Health and Fibromyalgia
The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map